IRCT20130917014693N10
Recruiting
Phase 3
Evaluation the efficacy and safety of Hydroxychloroquine administration for COVID-19 post exposure prophylaxis
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- COVID-19 pneumonia.
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age over 18 years old
- •Close contact with COVID\-19 patient at least in past 4 days
- •sign the informed consent form to participate in study
Exclusion Criteria
- •Pervious case of COVID\-19
- •Current case of COVID\-19
- •Presenting influenza like symptoms (fever, cough, and sore throat) in last 30 days
- •Travel history in last 14 days
- •Lactation and pregnancy
- •History of arrhythmia
- •Drug allergy history
- •Favism history
- •Chronic liver disease
- •Chronic kidney disease
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Treatment of Hydroxychloroquine in Type 2 Diabetes Patients Uncontrolled on Metformin MonotherapyHealth Condition 1: E119- Type 2 diabetes mellitus without complicationsCTRI/2021/11/037750Ipca Laboratories Ltd
Recruiting
Phase 1
Efficacy of hydroxychloroquine plus favipiravir drug regimen in comparison with hydroxychloroquine plus kaletra in hospitalized patients with COVID-19COVID-19.COVID-19U07.1IRCT20150808023559N20Ardabil University of Medical Sciences100
Completed
Phase 3
Comparison of the safety and efficacy of Favipiravir and kaletra in COVID-19IRCT20200318046812N1Iran University of Medical Sciences324
Recruiting
Phase 4
A Clinical Trial to Study the Safety and Efficacy of Hydroxychloroquine in Patients with Type-2 DaibetesHealth Condition 1: E118- Type 2 diabetes mellitus with unspecified complicationsCTRI/2016/02/006599Ipca Laboratories Ltd600
Recruiting
Phase 2
Combination therapy in COVID 19COVID-19 pneumonia.IRCT20100228003449N30Tehran University of Medical Sciences50